Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Astroulakis, Z.
Right arrow Articles by Hill, J. M.
PubMed
Right arrow Articles by Astroulakis, Z.
Right arrow Articles by Hill, J. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org

Does ‘SWITCHing’ from heparin to bivalirudin monotherapy result in a bleeding benefit?

Zoë Astroulakis and Jonathan M. Hill*

Cardiovascular Division, King’s College School of Medicine, London, UK

* Corresponding author. Tel: +44 20 7848 5218; fax: +44 20 7848 5193. E-mail address: jonathan.hill{at}kcl.ac.uk

Bleeding is the commonest non-ischaemic complication associated with percutaneous coronary intervention (PCI), leading to a substantial increase in morbidity and mortality rates. Until recently, this was accepted as an inherent risk associated with the use of antithrombotic and antiplatelet agents in the management of acute coronary syndromes (ACS). However, recent trials have shown that the direct thrombin inhibitor bivalirudin can be used safely and effectively at the time of PCI, significantly reducing rates of bleeding with equivalent rates of ischaemic complications. This article reviews the data from recent randomized controlled trials comparing the use of unfractionated/low molecular weight heparin plus glycoprotein (GP) IIb/IIIa agents with bivalirudin and presents the evidence suggesting that making the switch from heparin to bivalirudin monotherapy at the time of PCI does indeed confer a "bleeding benefit".

Key Words: Acute coronary syndromes • Percutaneous coronary intervention • Bleeding • Heparin • Bivalirudin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.